Cipla Q1FY27 profit falls 39% despite record India sales
Cipla’s consolidated net profit fell 39.2% year on year to Rs 789.05 crore, while revenue rose 2.3% to Rs 7,119.28 crore. Its India business grew 12%, supported by chronic-therapy launches and the obesity-drug partnership with Eli Lilly.
Cipla’s Q1FY27 profit fell 39% to Rs 789 crore despite record India sales, which grew 12%. The drugmaker expanded chronic-therapy offerings with Nintedanib and Dapagliflozin launches and is backing obesity drug Yurpeak under an Eli Lilly licensing agreement.
Why this matters
No prior related Cipla signals were provided. The Q1FY27 result pairs record India sales growth with a sharp profit decline, putting margins and business mix in focus.
Retail-company signals are accelerating, up 1,037,300% QoQ.